These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1097091)

  • 21. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients.
    Büchel B; Sistonen J; Joerger M; Aebi Y; Schürch S; Largiadèr CR
    Clin Chem Lab Med; 2013 Aug; 51(8):1681-8. PubMed ID: 23412878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of fluorouracil in humans.
    MacMillan WE; Wolberg WH; Welling PG
    Cancer Res; 1978 Oct; 38(10):3479-82. PubMed ID: 688233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
    Kobuchi S; Ito Y; Sakaeda T
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):707-718. PubMed ID: 27889876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).
    Cohen JL; Irwin LE; Marshall GJ; Darvey H; Bateman JR
    Cancer Chemother Rep; 1974; 58(5 Pt 1):723-31. PubMed ID: 4609602
    [No Abstract]   [Full Text] [Related]  

  • 28. [Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration].
    Hara Y; Kono A; Tanaka M
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2261-6. PubMed ID: 6237614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man.
    Almersjö OE; Gustavsson BG; Regårdh CG; Wåhlén P
    Acta Pharmacol Toxicol (Copenh); 1980 May; 46(5):329-36. PubMed ID: 7376884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Chun H; Martin D; Young C
    Cancer Treat Rep; 1985 Feb; 69(2):179-84. PubMed ID: 3971391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
    Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
    Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.
    Schaaf LJ; Dobbs BR; Edwards IR; Perrier DG
    Eur J Clin Pharmacol; 1987; 32(4):411-8. PubMed ID: 3609119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Yoshimoto M; Nishidai H; Nakanishi Y; Kashi Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1037-48. PubMed ID: 6721512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
    Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
    Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
    Finch RE; Bending MR; Lant AF
    Br J Clin Pharmacol; 1979 Jun; 7(6):613-7. PubMed ID: 465283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of oral and intravenous fluorouracil in humans.
    Phillips TA; Howell A; Grieve RJ; Welling PG
    J Pharm Sci; 1980 Dec; 69(12):1428-31. PubMed ID: 7463330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salivary excretion of 5-fluorouracil (5-FU). IV. Dependency of saliva/plasma concentration ratio and salivary clearance on plasma concentration of 5-FU during constant-rate intravenous infusion in rats.
    Hayashi Y; Watanabe J; Ozeki S
    J Pharmacobiodyn; 1989 Mar; 12(3):137-44. PubMed ID: 2760793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.